Condition
Hypoplasminogenemia
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03642691UnknownPrimary
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
NCT02690714Phase 2CompletedPrimary
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
NCT03265171UnknownPrimary
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
NCT02312180Phase 1Completed
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
Showing all 4 trials